270P - Prognostic value of residual disease in breast and nodes (RDBN), a histopathologic system to evaluate the response after neoadjuvant chemotherapy (...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Early Stage
Pathology/Molecular Biology
Presenter Vanesa Pons
Citation Annals of Oncology (2014) 25 (suppl_4): iv85-iv109. 10.1093/annonc/mdu327
Authors V. Pons1, J.A. Pérez-Fidalgo1, O. Burgués2, M.T. Martinez1, P. Martín1, B. Bermejo1, J.M. Cejalvo1, K. Pinilla1, A. Lluch-Hernandez1
  • 1Medical Oncology And Hematology Unit, Health Research Institute INCLIVA, 46010 - Valencia/ES



Many studies have shown the prognostic value of the complete pathological response after NAC in breast cancer. There are many histopathological classification systems but the most frecuently used are Miller-Payne and Residual Cancer Burden (RCB). The aim of this study is to validate a new one, Residual Disease in Breast and Nodes (RDBN).


In this retrospective study 318 patients treated in our institution between January 2005 and October 2012 with NAC were enrolled. 86,7% of the patients received an anthracycline and taxane based chemotherapy, asociated with trastuzumab in patients with overexpression/amplification of Her2. All patients with estrogen and/or progesterone receptor expression received endocrine therapy. For all of them RDBN was calculated taking into account tumour size, axillary lymph node involvement and histologic grade (HG). A correlation with survival was done using the Kaplan-Meier method and Cox regression model.


From the 318 patients included in this study, 8,2% had stage I tumours at diagnosis, 71,4% stage II and 20,4% stage III. 80,5% of the patients presented positivity for hormonal receptors and 31% for Her2. After the treatment, 14,77% had RDBN-I (pathological complete response), 37,11% RDBN-II, 30,18% RDBN-III and 17,92% RDBN-IV. Patients with RDBN-I had more frequently HG-III tumours without hormonal receptors expression. By contrast, RDBN-II to IV were associated to HG-II, positive hormonal receptors and no Her2 overexpression/amplification. Overall survival (OS) was 100% for RDBN-I, 99,4% for RDBN-II, 91,7% for RDBN-III and 71,9% for RDBN-IV, p < 0.001. Disease-free survival (DFS) was 91,5% for RDBN I-II patients, 82,3% for RDBN-III and 38,6% for RDBN-IV, p< 0.001.


RDBN is statistically asociated with OS and DFS.


All authors have declared no conflicts of interest.